PharmaNutra S.p.A.: results come from research

Published: 16 July 2019 10:07

The PharmaNutra group continues its rapid growth, with double-digit sales increases in the first six months of 2019, thanks to its research and development activities and numerous patents granted.

 

 

Double-digit growth continues – in terms of units sold, compared to the same period of the previous year – for PharmaNutra. For the period closed on 30ᵗʰ June 2019, the Group recorded a 12% increase in sales on the Italian market and 11% in its export markets.
 

 

These results bear witness to the quality of PharmaNutra products and their popularity on the market, following continuous investments in research and development, which today have generated 6 patents granted with a 20-year term (including: Iron-based solid composition, expiry 2032; Mineral-based solid composition and mouth-dispersible formulations, expiry 2033; Cetylated fatty acids, expiry 2035), supported by 91 clinical trials published and 27 studies in progress. Protecting our intellectual property rights, these figures are further strengthened by the 15 unique proprietary functional ingredients.
 

 

“This data confirms the many years’ commitment to research and development, as well as the investments made to obtain the patents already granted as well as 8 new patents pending, ensuring that the intellectual property of our products remains protected. These results encourage us to continue with our research, in order to guarantee the highest quality standards on the market, strengthen our leadership position in the nutritional supplements market and further develop our presence in export markets”, stated Roberto Lacorte, Vice President of PharmaNutra S.p.A.